Oct 23, 2006 by Brian LawlerThe New Schering-PloughGrowth returns, thanks to the company's diverse sales.
Oct 20, 2006 by Brian LawlerPfizer Keeps FightingNot a bad quarter for the big pharma, considering the challenges ahead.
Oct 20, 2006 by Brian LawlerCubist Paints a Greener PictureThe pharmaceutical company is flush with cash and finally profitable.
Oct 19, 2006 by Brian LawlerAmylin's One-Drug WonderDiabetes drug Byetta is set to boost Amylin's sales.
Oct 19, 2006 by Brian LawlerMarking Time at SeronoThings still look good for this soon-to-be-acquired Swiss pharma.
Oct 19, 2006 by Brian LawlerNo Gilded Quarter for GileadThe company's recent acquisition may help it become a diversified drug giant.
Oct 19, 2006 by Brian LawlerWhere Are The Earnings, USANA?Sales grew, but earnings didn't, compared to last year's third quarter.
Oct 19, 2006 by Brian LawlerA Yawn and More Growth From WyethThe numbers aren't all that new, but they are good.
Oct 18, 2006 by Brian LawlerAnother Hard Pill to SwallowA former FDA chief will take the fall for not disclosing holdings, but the pharmaceuticals industry needs more than that.
Oct 18, 2006 by Brian LawlerSeeing the Forest Through the TreesUnderappreciated Forest Labs continues its trend of strong growth.
Oct 18, 2006 by Brian LawlerIs a Buyback the Best Abbott Can Do?Abbott Labs may be out of ideas for its cash.
Oct 17, 2006 by Brian LawlerRoche RocksThe Swiss pharma has a stable of hot brands and lots of promise in the pipeline.
Oct 17, 2006 by Brian LawlerSee Johnson & Johnson CrawlEarnings growth isn't moving right along because the company has become so big.
Oct 17, 2006 by Brian LawlerLilly Doesn't Like Sharing ProfitsThe company is buying out ICOS Corporation, its partner in erectile-dysfunction drug Cialis.
Oct 16, 2006 by Brian LawlerBayer's Big Drug Boo-BooThe company's forgetfulness could end up hurting its reputation even worse than its revenues.
Oct 16, 2006 by Brian LawlerNegative Revenue Surprise From AsprevaShares dropped last week when the company announced it won't meet analysts' guidance for third-quarter revenue.
Oct 16, 2006 by Brian LawlerThe Coming Generic Drug BoomGeneric drugmakers are poised to profit from several key factors.
